Biosimilar brand buy to help Intas Pharma take on biggies
06 February 2025
In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.
Intas Pharmaceuticals' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon, Amgen, Pfizer, Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.
In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.
Intas Pharmaceuticals' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon, Amgen, Pfizer, Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Pre Ipo
Upcoming IPO
Unicorn
Planify Enterprises Private Limited
Planify Capital Limited
Licensed By
Mutual Fund License No.:
ARN-164419
IRDA Code (1):
ABLIC1003123454
IRDA Code (2):
ABLIC1003131639
Startup India Certificate No.:
DIPP93786
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India
